Complement Activation and Thrombotic Microangiopathies.
Marta PalomoMiquel BlascoPatricia MolinaMiquel LozanoManuel PragaSergi Torramade-MoixJulia Martinez-SanchezJoan CidGines EscolarEnric CarrerasCristina PaulesFatima CrispiLuis F QuintanaEsteban PochLida RodasEmma GomaJohann MorelleMario EspinosaEnrique MoralesAna AvilaVirginia CabelloGema AricetaSara ChocronJoaquin ManriqueXoana BarrosNadia MartinAna HuertaGloria M Fraga-RodriguezMercedes CaoMarisa MartinAna Maria RomeraFrancesc MoresoAnna ManonellesEduard GratacosArturo PereiraJosep M CampistolMaribel Diaz-RicartPublished in: Clinical journal of the American Society of Nephrology : CJASN (2019)
The proposed methodology identifies complement overactivation in patients with atypical hemolytic uremic syndrome at acute phase and in other diseases such as HELLP syndrome and preeclampsia. Moreover, it is sensitive enough to individually assess the efficiency of the C5 inhibition treatment.